Michael has 20 years of global ophthalmic leadership experience across pharmaceuticals, drug delivery and medical devices.He was appointed President & CEO of GrayBug in 2013, a new ocular pharmaceutical and drug delivery company developing new therapeutics in w-AMD and glaucoma.Previous experience includes General Manager for Bausch + Lomb Pharmaceuticals, Chiron Vision Europe, Alza, Pfizer and 3M Pharma. Michael has managed 26 brands, led 13 product launches, and has been a team member in 19 device/drug approvals.He is Foundation Board Chairman for Lions Eye Institute, the world’s largest Eye Bank with a unique Ocular Research Center.

Ocular Immunology,Ocular Oncology